Pregnancy outcome of women transfused during pregnancy with blood products inadvertently obtained from donors treated with acitretin.
We assessed the pregnancy outcome of nine women inadvertently transfused with acitretin-contaminated blood products in South Korea. A total of 18 women matched to cases by age, gravidity, and singleton- or twin-pregnancy, and who were transfused with blood products not contaminated with acitretin, was also recruited. There were nine babies born in the case group. No differences (p > 0.05) were observed between cases and controls in the gestational age at delivery (38.3 +/- 1.6 weeks vs 37.8 +/- 2.2 weeks), birth weight (3,146 +/- 874 g vs 3,106 +/- 568 g), rate of pre-term deliveries (22.2% vs 11.1%) and rate of low birth weight (<2,500 g) (33.3% vs 16.7%). There was no case of malformation or neurological abnormalities born in either group. In conclusion, inadvertent exposure to acitretin-contaminated blood products was not associated with adverse pregnancy outcomes, probably because of the removal of acitretin and etretinate during the manufacturing process of blood products.
Han
J Y
JY
Korean Motherisk Program, Department of Obstetrics and Gynecology, Cheil Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea. hanjungyeol@yahoo.com
Choi
J S
JS
Chun
J M
JM
Park
H D
HD
Lee
S Y
SY
Kim
C H
CH
Park
Q
Q
Nava-Ocampo
A A
AA
Koren
G
G
D017255:Acitretin / Q000097:blood*; D000328:Adult; D001688:Biological Products / Q000737:chemistry*; D016022:Case-Control Studies; D004340:Drug Contamination; D005260:Female; D005865:Gestational Age; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D007641:Keratolytic Agents / Q000097:blood*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy; D013723:Teratogens; D065227:Transfusion Reaction
D001688:Biological Products; D007641:Keratolytic Agents; D013723:Teratogens; D017255:Acitretin